Organizers: Mercedes Beyna (Pfizer), Mark Kaplan (Pfizer), Laurent Yvan-Charvet (Pfizer), and Jennifer Henry (The New York Academy of Sciences)Presented by Hot Topics in Life Sciences
Reported by Alan Dove | Posted March 1, 2013
Every year, millions of people develop myocardial infarctions, commonly known as heart attacks, in which a loss of blood flow causes a portion of the heart muscle to die. Current treatments can save upwards of 80% of these patients, but the underlying condition that causes infarction, ischemic heart disease, often leads to chronic, life-shortening problems. According to the World Health Organization, ischemic heart disease accounts for about 12% of deaths worldwide.
On December 14, 2012, the New York Academy of Sciences presented Novel Therapeutic Targets in Myocardial Infarction, a Hot Topics in Life Sciences symposium which highlighted new strategies and technologies, as well as the significant challenges this condition presents. Speakers discussed new treatments, like cellular repair through bone marrow-derived mononuclear cells and efferocytosis; new findings on the dual role of inflammatory processes; avenues opened through nanotechnology; insights from genome analysis; and novel techniques for measuring endothelial damage. The symposium also delved into one of the field's toughest challenges, predicting heart attacks, and looked at the events following an infarction, when the heart repairs and remodels injured tissue. Though much of this research highlights the deep complexity of ischemic heart disease, it also reveals new treatment possibilities.
Use the tabs above to find a meeting report and multimedia from this event.
Presentations available from:
Paddy Barrett, MD (Scripps Translational Science Institute)
Buddhadeb Dawn, MD (University of Kansas Medical Center)
Zahi A. Fayad, PhD (Mount Sinai School of Medicine)
Barbara Hempstead, MD, PhD (Weill Cornell Medical College)
Elizabeth McNally, MD, PhD (The University of Chicago Medicine)
Filip Swirski, PhD (Massachusetts General Hospital; Harvard Medical School)
Edward Thorp, PhD (Northwestern University)
Bristol-Myers SquibbLog in or Join Now to continue